Immunological
Over 140 biopharma leaders share their views on developments to watch for in key therapeutic areas this year. Advances in multiple scientific fields are opening up new avenues for treatment.
Argenx has discontinued Vyvgart for the rare skin disease as other potential candidates linger in the very early stages of development.
Alumis said it will pause the planned Phase III program for Acelyrin’s lead drug and assess the value of the candidate, which produced underwhelming Phase II results in January.
Scrip surveys some of the more interesting Phase III clinical trial readouts expected this year.
The company ended the year with financial momentum and will initiate clinical trials for its anti-TL1A in atopic dermatitis and MASH on top of late-stage studies ongoing in IBD.
CEO Paul Hudson has declared that “immunology is effectively our obesity” and the French firm is looking to use its position of strength in the space and its healthy cash pile to bring in early-stage assets.
CEO Djordje Filipovic tells Scrip that after talks with "multiple other potential partners,” the firm chose the Japanese group for its expertise and marketing capabilities in rare diseases” to be the licensing partner for tadekinig alfa in the US.
The TYK2 inhibitor is in Phase III development for plaque psoriasis and psoriatic arthritis but the company said it will not pursue late-stage studies in lupus, partly due to the Inflation Reduction Act.
The FDA has approved the IL-23 inhibitor for Crohn's disease to add to its ulcerative colitis approval and put the drug in a position to compete with the likes of AbbVie's Skyrizi and Johnson & Johnson's Stelara.
The US biotech is paying $250m upfront to the Danish group in what is the second STAT6 deal secured in the past three weeks.
The company’s IgG antibody constructs have now failed in oncology and autoimmune disease, leaving it with few remaining strategic options.
The French biotech plans to file for EMA approval in graft-versus-host disease in mid-2025 while starting a US Phase III trial, which the CEO said in an interview is contingent on financing.
The company reported positive Phase II data from the BEACON trial testing the c-Kit inhibitor in chronic spontaneous urticaria and said it is planning a Phase IIb/III program.
With new Phase I/II data for its anti-IGF-1 agent lonigutamab, Acelyrin will move into Phase III in thyroid eye disease. But how competitive it will be versus Tepezza or Viridian’s Phase III candidate is uncertain.
While quieter than some recent years, 2024 did produce several clinical trial readouts destined to have an impact on their respective markets. Here, in roughly chronological order, Scrip takes a look at the 10 clinical stories that got readers clicking the most over the past 12 months.
The biopharma sector has once again experienced highs and lows this year. With just a week left, and in no particular order, Scrip takes a look at five of the biggest stories of 2024.
CytoCares’ CEO shares plans for CC312, a potentially first-in-class trispecific antibody for autoimmune disorders it sees as differentiated from global rivals.
Certa and OccuRx both came out of Fibrotech and are now joining forces to advance asengeprast as a potential therapy for scleroderma and focal segmental glomerulosclerosis.
Looking to compete with Amgen’s Tepezza, veligrotug has now met efficacy and safety endpoints in active and chronic patients, while offering less burdensome dosing.
The French group says it can only fund operations in the first quarter of 2025 but having secured “a clear and reasonable pathway towards an accelerated approval” after talks with the US Food and Drug Administration for its Viaskin Peanut patch in toddlers, the future is looking much brighter.